Xilio Therapeutics (XLO) catalysts

Upcoming FDA decisions and readouts we track for Xilio Therapeutics, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 12 Sep 2026

FreeBioList tracks 1 upcoming catalyst for Xilio Therapeutics (XLO, listed on Nasdaq). It concerns XTX501 (Metastatic NSCLC (masked PD-1/IL-2 bispecific)).

First on the list: the Phase 1 readout for XTX501 (Metastatic NSCLC (masked PD-1/IL-2 bispecific)), guided by the company to H2 2027.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.

Background reading: Clinical trial phases explained: Phase 1 to Phase 4.

Ticker: XLO
Next catalyst: H2 2027
Type: Phase 1 readout
Listed options: No

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Xilio Therapeutics XLO · Nasdaq	XTX501	Metastatic NSCLC (masked PD-1/IL-2 bispecific)	H2 2027 company guidance	Phase 1 readout	Verified	8-K exhibit 99.1 ↗	No
Notes — Filing states "Xilio plans to report initial Phase 1 data in patients with metastatic NSCLC in the second half of 2027." Source: 8-K exhibit 99.1, filed 12 Aug 2026 · verified 12 Sep 2026

Companies working on related conditions

Compass Therapeutics (CMPX)Biliary tract cancer (DLL4 x VEGF-A bispecific); TNBC, NSCLC and Hodgkin lymphoma post-checkpoint (PD-1 x PD-L1); Solid tumours (PD-1 x VEGF-A bispecific)
ArriVent BioPharma (AVBP)First-line EGFR exon 20 insertion NSCLC
Cullinan Therapeutics (CGEM)EGFR exon 20 insertion NSCLC, second line
CytomX Therapeutics (CTMX)Metastatic colorectal cancer (EpCAM ADC); Metastatic colorectal cancer; Advanced melanoma (masked interferon alpha-2b)
Eikon Therapeutics (EIKN)Non-squamous NSCLC (TLR7/8 agonist); Melanoma — first interim analysis; Advanced solid tumours (PARP1-selective); Advanced solid tumours (WRN helicase inhibitor
Whitehawk Therapeutics (WHWK)EGFR wild-type NSCLC, platinum-resistant ovarian and endometrial cancer; Advanced ovarian and endometrial cancers